vonoprazan (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Helicobacter pylori Infection

Pending FDA approval for treatment of Helicobacter pylori (H pylori) infection as triple therapy (in combination with amoxicillin and clarithromycin) or dual therapy (in combination with amoxicillin)

Next:

Pharmacology

Mechanism of Action

Potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach

P-CABs inhibit binding of potassium ions to H+, K+ -ATPase (ie, the proton pump) in the final step of gastric acid secretion in gastric parietal cells, thereby increasing intragastric pH

Vonoprazan has alkaline pKa of 9.06, which enables a high level of accumulation in acid space (eg, intracellular canaliculi of the parietal cells)

Purported advantages of vonoprazan over conventional proton-pump inhibitors (PPIs), including rapid onset of action, long duration of acid suppression, fewer interindividual variations in terms of acid suppression, and minimum dietary influence on its action

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.